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Resolution of type 2 diabetes after gastrectomy for 
gastric cancer with long limb Roux-en Y reconstruction: 
a prospective pilot study
Whan Sik Kim, Jong Won Kim, Chul Woo Ahn1, Seung Ho Choi
Departments of Surgery and 1Endocrinology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Purpose: It is unclear whether metabolic surgery is effective in non obese type 2 diabetes mellitus (T2DM) and the result after 
gastrectomy and conventional reconstruction for gastric cancer with non obese T2DM are not satisfactory for improvement 
of T2DM. Prospective single-arm pilot study with long limb Roux-en Y reconstruction after gastrectomy was evaluated on its 
safety and efficacy as a potential cure for T2DM in patients with non obese gastric cancer. Methods: Fifteen patients with non 
obese T2DM and gastric cancer were enrolled. After gastrectomy, the gastrointestinal tract was reconstructed by Roux-en Y 
gastrojejunostomy or esophagojejunostomy. The biliopancreatic and Roux limb were 100 to 120 cm long each. Results: There 
was no surgery-related mortality, but four cases experienced complications (26.7%). Before surgery, the mean body mass in-
dex was 25.2 ± 3.4 kg/m2 and mean glycated hemoglobin (HbA1c) was 7.7 ± 1.4% with antidiabetic medications. The mean 
BMI decreased to 21.7 ± 3.1 kg/m2 (P ＜ 0.05) and the mean HbA1c decreased to 6.3 ± 0.8% (P ＜0.05) 6 months after surgery. 
At the end of the study (follow-up duration, 12.5 ± 5.5 months), HbA1c decreased to ＜6% in 11 patients (78.6%) without any 
antidiabetic medications. There were no patients who had anemia, and/or malnutrition after surgery except one patient who 
died due to recurrence four months after surgery. Conclusion: Long limb Roux-en Y reconstruction after gastrectomy is fea-
sible and has the potential to cure T2DM in non obese gastric cancer patients. A randomized controlled trial is needed to con-
firm this result.
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INTRODUCTION
The care of patients with type 2 diabetes mellitus 
(T2DM) should focus not only on glucose control but also 
on management of complications such as heart disease, 
dyslipidemia, obesity, and cancer. However, the preva-
lence of adult diabetes has been rising globally [1,2] and 
the economic and social burdens of diabetes threaten the 
world’s health systems [3,4].
It has been demonstrated that metabolic surgery re-
solves T2DM in morbidly obese patients [5-7]. In contrast, 
whether metabolic surgery is effective in nonmorbidly 
obese patients still remains to be solved. Moreover, Asian 
people develop T2DM at a younger age with a lesser de-
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gree of obesity, and tend to have the complications and die 
earlier [8,9].
As life expectancy is increased, the number of patients 
with gastric cancer and T2DM is increased as well. It was 
noticed that gastric resection induce the resolution of 
T2DM in non-morbidly obese patients [10-12]. 
Recently, we studied the outcome of T2DM after gas-
trectomy and conventional reconstruction in non obese 
gastric cancer patients [13]. The study was a large-series 
retrospective study including about 400 patients and only 
15.1% were resolved from T2DM after operation, which 
were not satisfactory. This prompted us to develop a effec-
tive reconstruction method for diabetic control after gas-
trectomy in gastric cancer patients with non obese T2DM. 
We grafted the bariatric type operation, long-limb 
Roux-en Y reconstruction into gastric cancer surgery. This 
study aimed to investigate the safety and efficacy of long 
limb Roux-en Y reconstruction after gastrectomy in non 
obese gastric cancer patients.
METHODS
Study design
This was a prospective pilot study to evaluate the safety 
and efficacy of long limb Roux-en Y reconstruction after 
gastrectomy as a potential cure for T2DM in non obese 
gastric cancer patients. The study was based on a protocol 
determined by the Departments of Surgery and Endocrin-
ology of Gangnam Severance Hospital and was approved 
by the Institutional Review Board of this hospital (# 
3-2009-0152). Each patient was informed of the investiga-
tional nature of the trial and received detailed information 
regarding the study protocol. All patients provided writ-
ten informed consent before their enrollment in the trial. 
The study was also registered on the ClinicalTrials.gov 
website (http://www.clinicaltrials.gov/) (NCT01373346).
Patients were eligible for the study if they had a history 
of T2DM over 6 months, a body mass index (BMI) ＜30 
kg/m2, and underwent curative resection for gastric cancer. 
Patients were required to have their C-peptide above 1 
ng/mL. Candidates were excluded if they had anti-gluta-
mic acid decarboxylase  antibody and/or islet cell antibody, 
and had a history of recently receiving medications such 
as dipeptidyl peptidase-IV inhibitors or glucagon-like 
peptide-1 analogues. The enrollment continued from 
February 2010 through May 2011. Baseline weight/height, 
vital signs, oral glucose tolerance test score, and levels of 
fasting plasma glucose (FPG), glycated hemoglobin 
(HbA1c), C-peptide, and serum insulin were measured 
before surgery and again regularly after surgery. Insulin re-
sistance was measured by the insulin sensitivity index [14] 
homeostasis model assessment (HOMA)-insulin resistance 
[15] and quantitative insulin sensitivity check index 
(QUICKI) [16] using a web calculator (http://mmatsuda. 
diabetes-smc.jp/MIndex.html, https://sasl.unibas.ch/ 
11calculators-QUICKI.php). Insulin secretion was meas-
ured by HOMA-derived beta-cell function (HOMA-B) 
(HOMA-B = 225 × 18/fasting insulin × fasting glucose) [17]. 
The safety of this procedure was evaluated by mortality 
and morbidity rates. Because the procedure was not so dif-
ferent from conventional gastric cancer surgery except the 
length of Roux limb and biliopancreatic limb, the rate of 
Roux stasis or A-loop syndrome was specifically evaluated.
Operative procedure
All patients underwent radical gastrectomy under gen-
eral anesthesia and D1 + lymph node dissection was ap-
plied into early gastric cancer and D2 lymph node dis-
section in advanced gastric cancer [18]. 
The gastrointestinal tract was reconstructed by Roux-en 
Y gastrojejunostomy or esophagojejunostomy with ante-
colic fashion. The jejunum was divided at approximately 
100 to 120 cm distal to the ligament of Treitz and the distal 
limb of the jejunum was then anastomosed along the prox-
imal gastric greater curvature or esophagus. The jejuno-je-
junostomy was performed approximately 100 to 120 cm 
distal from the gastrojejunal or esophagojejunal anasto-
mosis (Fig. 1).
Statistical analysis
Continuous variables were expressed as mean ± stand-
ard deviation (range). Demographic and baseline charac-
teristics were summarized descriptively, and the changes 
in the observation parameters at baseline and endpoint 
were analyzed using the Wilcoxon signed rank test. A two 
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Fig. 1. Long limb Roux-en Y anastomosis. After gastrectomy, the gastrointestinal tract was reconstructed by Roux-en Y gastrojejunostomy (A)
or esophagojejunostomy (B). The biliopancreatic and Roux limb were 100 to 120 cm long each.
Table 1. Preoperative demographic data of 15 patients
Characteristic Value
Duration of type 2 diabetes mellitus (mo) 136.9 ± 102.4
Antidiabetic medication
  Insulin 1 (6.7)
  Insulin ＋ oral 1 (6.7)
  Oral 13 (86.7)
Serum insulin level (μIU/mL) 8.1 ± 6.8
Serum C-peptide level (ng/mL) 2.2 ± 1.2
Values are presented as mean ± standard deviation or number (%). 
sided P-value of 0.05 was considered statistically signi-
ficant. All statistical analyses were performed using of 
PASW ver. 18.0 (IBM Co., Armonk, NY, USA). 
RESULTS 
A total of 15 non obese T2DM patients with gastric can-
cer were enrolled. There were 10 males and 5 females and 
their mean age was 62.1 ± 8.7 years. The baseline demo-
graphic data are presented in Table 1. Four patients re-
ceived total gastrectomy and 11 patients received subtotal 
gastrectomy. Eleven patients received laparoscopic oper-
ation
The mean surgical time was 265.5 ± 84.8 minutes. There 
was no surgery-related mortality, but four patients experi-
enced complications; one experienced anastomotic stric-
ture that was recovered with conservative management, 
one experienced anastomosis site kinking managed with 
temporary stent insertion and one had myocardial in-
farction treated with percutaneous transluminal coronary 
angioplasty with stent insertion. There was one wound 
complication. There were no patients who were com-
plaints of Roux stasis or A-loop syndrome. Final patho-
logic results revealed that nine patients were early gastric 
cancer and six patients were advanced. Four patients re-
ceived chemotherapy. During the follow-up period, there 
was one patient who had poorly differentiated neuro-
endocrine carcinoma and died due to recurrence four 
months after surgery, but the blood glucose level was well 
controlled (HbA1c ＜ 6.0%) without medication. In the re-
mained patients, there was no evidence of recurrence in 
the regular check-up at 6 months after operation. Also, 
there was no stricture or jejunal ulcer in the follow-up en-
doscopic examination.
The patient who died of recurrence was excluded from 
the efficacy evaluation. Six months after surgery (n = 14), 
the mean BMI was significantly decreased to 21.7 ± 3.1 
kg/m2 from 25.2 ± 3.4 kg/m2 (P ＜ 0.05). The preoperative 
mean HbA1c was 7.7 ± 1.4% with antidiabetic medications 
and the mean HbA1c was also significantly down to 6.3 ± 
0.8% (P ＜ 0.05).
At the end of the study, the follow-up duration was 12.5 
± 5.5 months (6.0 to 21.7 months). HbA1c ＜ 6% without 
any antidiabetic medications were observed in 11 patients 
(78.6%). A total of four patients who received total gas-
trectomy and seven patients (70%) who received subtotal 
gastrectomy were included. All of four patients who re-
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Table 2. Outcome of patients showing HbA1c ＜6% without the antidiabetic medication after surgery (n = 11)
Preoperative After surgery (6 mo) P-valuea) The end of study P-valueb)
ISI 5.7 ± 3.0 14.0 ± 6.1 0.028 12.7 ± 7.3 0.075
HOMA-IR 1.9 ± 1.9 0.9 ± 0.7 0.033 0.8 ± 0.6 0.026
QUICKI 0.4 ± 0.1 0.4 ± 0.0 0.169 0.5 ± 0.1 0.017
HOMA-B 8.7 ± 6.9 13.4 ± 8.9 0.169 17.8 ± 12.3 0.047
Hemoglobin (g/dL) 13.3 ± 1.8 12.6 ± 1.8 0.091 13.0 ± 1.7 0.507
Albumin (g/dL) 4.4 ± 0.4 4.2 ± 0.6 0.139 3.9 ± 0.7 0.011
Triglyceride (mg/dL) 117.7 ± 55.5 98.1 ± 62.9 0.510 88.6 ± 66.8 0.368
Cholesterol (mg/dL) 139.0 ± 32.4 123.3 ± 27.4 0.233 123.4 ± 34.5 0.287
Values are presented as mean ± standard deviation. 
HbA1c, glycated hemoglobin; ISI, insulin sensitivity index; HOMA-IR, homeostasis model assessment-insulin resistance; QUICKI, 
quantitative insulin sensitivity check index; HOMA-B, homoeostasis model assessment-derived beta-cell function. 
a)Preoperative versus postoperative 6 months values. b)Preoperative versus the end of study values.
ceived chemotherapy discontinued anti-diabetic medi-
cation after operation. Although improvement of insulin 
sensitivity was unstable, insulin secretion was sig-
nificantly improved (P ＜ 0.05) (Table 2). The FPG levels of 
2 patients (14.3%) were between 6.1 and 7.0 mmol/L and 
their HbA1c were well controlled (between 6% and 7%) 
with or without medications. Only one patient had HbA1c 
above 7%, but the FPG and 2-hour plasma glucose levels 
were significantly decreased after surgery. There were no 
patients who had anemia, and/or malnutrition after 
surgery. Even though the albumin levels were decreased 
at the end of study compared to the preoperative levels, 
they were still within normal range. Also, the levels of se-
rum triglyceride and serum cholesterol decreased after 
operation, but remained in normal range.
DISCUSSION
Calorie restriction and/or weight loss are one of many 
effective ways to control T2DM in morbidly obese 
patients. However, calorie restriction and/or weight loss 
are not easy in non obese patients, and Asian people devel-
op T2DM with a lesser degree of obesity. 
The early recovery course and mismatched degree of 
T2DM improvement after gastric bypass compared with 
equivalent weight loss from other treatment modalities 
implicate weight-independent effects of bariatric surgery 
on glucose metabolism [6,19].  In addition, some reported 
that non-morbidly obese patient with T2DM can be recov-
ered after bariatric surgery [20-25]. These results sug-
gested that surgery might induce remission even in non 
obese T2DM patients. 
We had studied the long-term results of gastrectomy 
and conventional reconstruction in non obese T2DM pa-
tients with gastric cancer [13]. It was a very large scale 
study and the complete remission was only 27.3% even 
though in total gastrectomy and Roux-en Y esopha-
gojejunostomy. There were some reports that demonstrate 
the effect of subtotal gastrectomy and Roux-en Y gastro-
jejunostomy on T2DM in non obese patients, but the re-
mission rate was still not high [12]. Before we started this 
study, we tried some modifications of Roux limb length af-
ter gastrectomy and were not able to control glucose ho-
meostasis without medications in gastric cancer and 
T2DM patients. In this study, we tested the safety and effi-
cacy of Roux-en Y reconstruction with a 100-cm bil-
iopancreatic limb and a 100-cm Roux limb after gas-
trectomy in T2DM gastric cancer patients. The main differ-
ence with previous reports was the longer length of bil-
iopancreatic and Roux limbs. 
Among 15 patients enrolled in this study, 9 patients re-
ceived laparoscopic surgery with two anastomotic stric-
ture or kinking. We assumed that this complication was re-
lated with technical failure in the learning period.
Rearrangement of the intestine and/or modification of 
the stomach might induce functional obstruction of the 
small bowel and metabolic problems such as vitamin and 
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trace element deficiencies [26]. Longer length of a Roux 
limb has been suggested to be effective in super obese pa-
tients without significant complications [27]. In this study, 
we found that there was no Roux stasis syndrome, anemia 
and hypoalbuminemia after surgery. Some patients com-
plained of frequent diarrhea after eating fatty food, but 
normal diet was tolerable without malnutrition. In addi-
tion, most patients maintained their weight within normal 
range after surgery. 
Mechanisms of antidiabetic effects after gastrointestinal 
surgery are not yet fully characterized. Except effects due 
to weight loss and calorie restriction, exclusion of the 
proximal small intestine from ingested nutrient, enhanced 
distal-intestinal nutrient delivery, impaired ghrelin secre-
tion, modulations of intestinal nutrient sensing and regu-
lation of insulin sensitivity, bile acid perturbations, chan-
ges in gut microbiota and other changes were proposed 
[19,28]. Our study showed that all of patients who re-
ceived total gastectomy and/or chemotherapy stop the an-
ti-diabetic medication with normal glucose level and these 
might result from weight loss or calorie restriction. 
However, seven among ten patients who received subtotal 
gastrectomy without chemotherapy demonstrated nor-
mal glucose control after operation. In this study, by-
passed segments of the small bowel were longer than con-
ventional Roux-en Y reconstruction after gastrectomy. 
Also, nutrient stimulation of lower intestinal hormones 
(e.g., GLP-1) might be enhanced in the patients of this 
study. It was beyond the scope of this study to elucidate 
the mechanism by which T2DM was resolved. However, 
insulin secretion was significantly improved after surgery. 
We were afraid that the β cell function in non obese T2DM 
patients was decreased and such decrease might be 
irreversible. Fortunately, animal experiments demon-
strated that T2DM in lean T2DM rats can be improved by 
rearrangement of the gastrointestinal tract without sig-
nificant weight loss [29,30]. As mentioned above, these re-
sults are consistent with some human trials [20,21,24,25]. 
Now, we suggest that even when weight is maintained 
within the normal range, T2DM is still reversible in non 
obese patients. In this study, the improvement of insulin 
sensitivity was not clear. A long term follow-up study with 
increased enrolled patients is warranted to elucidate the 
improvement of insulin sensitivity. 
Taken together, we considered that long limb Roux-en Y 
reconstruction is feasible and has the potential to cure 
T2DM in gastric cancer patients. This was a pilot study and 
the duration of follow-up was short. To confirm the effec-
tiveness of long limb Roux-en Y procedure, randomized 
controlled trial (RCT) is needed and our results will be 
helpful to design the RCT. 
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